{"id":"W3047494536","doi":"10.1136/jitc-2020-000883","title":"An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Institute of Cancer Research; Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Foundation; Canada Research Chairs; AstraZeneca; Celgene; Canadian Institutes of Health Research; AstraZeneca Canada","keywords":"Durvalumab; Medicine; Regimen; Hypomethylating agent; Internal medicine; Adverse effect; Breast cancer; Oncology; Gastroenterology; Immunology; DNA methylation; Cancer; Immunotherapy; Nivolumab; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004913783,0.0001396699,0.0003403641,0.00005636467,0.0001201353,0.00003388209,0.0002600568,0.00006367041,0.00001005013],"category_scores_gemma":[0.0000490227,0.0001289487,0.000034501,0.0000987124,0.00003653126,0.00002957979,0.0000552491,0.0001034958,2.774336e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001950567,"about_ca_system_score_gemma":0.00009477697,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001414595,"about_ca_topic_score_gemma":0.0001751547,"domain_scores_codex":[0.9987665,0.0001102484,0.0005619827,0.0002386503,0.0001546087,0.0001679964],"domain_scores_gemma":[0.9991412,0.00001255891,0.0004036433,0.0001777139,0.0001689498,0.00009597083],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00195438,0.002718042,0.001653686,0.00001428642,0.00009299502,0.00000121576,0.001298338,0.001064096,0.8184182,0.000001246863,0.000002985769,0.1727805],"study_design_scores_gemma":[0.06238514,0.04637511,0.007422253,0.00005992715,0.00004696776,0.000002839951,0.001513849,0.005645359,0.8741875,0.0001221786,0.001916714,0.000322113],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932563,0.005331212,0.0005563222,0.00006991144,0.0001094407,0.0006398077,0.00002516522,0.000002268793,0.00000957505],"genre_scores_gemma":[0.9939547,0.001434516,0.004306542,0.0001067223,0.00009185578,0.00003804529,0.00001402746,0.00003176771,0.0000218058],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1724584,"threshold_uncertainty_score":0.5258377,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0510288598174325,"score_gpt":0.4253666546034957,"score_spread":0.3743377947860632,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}